Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Oxurion NV
  6. News
  7. Summary
    OXUR   BE0003846632

OXURION NV

(OXUR)
  Report
Real-time Euronext Bruxelles  -  11:35 2022-09-23 am EDT
0.1640 EUR   +7.89%
09/12Oxurion To Participate in Upcoming Scientific and Investor Conferences
GL
09/12Oxurion To Participate in Upcoming Scientific and Investor Conferences
AQ
09/07Oxurion Publishes First Half 2022 Results
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Oxurion Announces Presentations at Upcoming Scientific and Investor Conferences

07/11/2022 | 01:01pm EDT

Leuven, BELGIUM, Boston, MA, US July 11, 2022 – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today participation in two upcoming conferences.

American Society of Retina Specialists 2022 Annual Meeting – New York, NY
Date: Saturday, July 16, 2022 | 1:29 p.m. ET

Title: “A Phase 2 study of THR-149, a Plasma Kallikrein Inhibitor, in Subjects with DME who Respond Suboptimally to anti-VEGF Treatment (Month 6 Results of Part A of the KALAHARI study),” presented by Rahul Khurana, MD.

THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of diabetic macular edema (DME) patients showing suboptimal response to anti-VEGF therapy. Oxurion is evaluating THR-149 for the treatment of DME in Part B, the second part of its two-part Phase 2 KALAHARI trial.

H.C. Wainwright & Co., 2nd Annual Ophthalmology Virtual Conference
Date: Wednesday, August 17, 2022 | On-demand

Tom Graney, CEO of Oxurion, is available for one-on-one meetings and will deliver a pre-recorded presentation, available on-demand.

Both presentations will be available in the “Investors” section of the Company’s website.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

For further information please contact:

Oxurion NV
Tom Graney
Chief Executive Officer
Tel: +32 16 75 13 10
tom.graney@oxurion.com

 

Michael Dillen
Chief Business Officer
Tel: +32 479 783583
michael.dillen@oxurion.com

 
US
Conway Communications
Beth Kurth
bkurth@conwaycommsir.com

 

 

ICR Westwicke
Christopher Brinzey
Tel: +1 617 835 9304
Chris.Brinzey@westwicke.com

 

Attachment


All news about OXURION NV
09/12Oxurion To Participate in Upcoming Scientific and Investor Conferences
GL
09/12Oxurion To Participate in Upcoming Scientific and Investor Conferences
AQ
09/07Oxurion Publishes First Half 2022 Results
GL
09/07Oxurion Publishes First Half 2022 Results
GL
09/07OXURION NV : 1st-half-year results
CO
09/07OXURION NV : Half-year report
CO
09/06OXURION : Prospectus for the admission to trading on Euronext Brussels of up to 30,500,000..
PU
09/02OXURION : Special report of the Board of Directors
PU
09/02Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in ..
GL
09/02Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in ..
GL
More news
Financials
Sales 2022 0,66 M 0,64 M 0,64 M
Net income 2022 -23,8 M -23,1 M -23,1 M
Net Debt 2022 - - -
P/E ratio 2022 -0,35x
Yield 2022 -
Capitalization 8,70 M 8,46 M 8,46 M
Capi. / Sales 2022 13,2x
Capi. / Sales 2023 13,2x
Nbr of Employees 42
Free-Float 85,7%
Chart OXURION NV
Duration : Period :
Oxurion NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OXURION NV
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 0,16 €
Average target price 1,25 €
Spread / Average Target 662%
EPS Revisions
Managers and Directors
Thomas Graney Chief Executive Officer
Patrik de Haes Non-Executive Chairman
Grace Chang Chief Medical Officer
Alan Stitt Chief Scientific Officer
Claude Sander Secretary, Chief Legal & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
OXURION NV-90.97%8
MODERNA, INC.-51.32%48 368
IQVIA HOLDINGS INC.-32.86%35 330
LONZA GROUP AG-41.68%33 599
SEAGEN INC.-9.96%25 673
ALNYLAM PHARMACEUTICALS, INC.18.40%24 099